- Conditions
- Multiple Myeloma
- Interventions
- Spectra Optia Apheresis System
- Device
- Lead sponsor
- Terumo BCT
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Indianapolis, Indiana • Durham, North Carolina + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Sickle Cell Disease
- Interventions
- Red blood cell exchange in sickle cell
- Device
- Lead sponsor
- Terumo BCT
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Oakland, California • Aurora, Colorado + 2 more
- Conditions
- Healthy Apheresis Donors, Mononuclear (MNC) Cell Donors
- Interventions
- Spectra Optia CMNC, COBE Spectra MNC, Granulocyte-colony stimulating factor (G-CSF)
- Device · Drug
- Lead sponsor
- Terumo BCT
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Memphis, Tennessee
- Conditions
- Respiratory Failure, ARDS
- Interventions
- Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)
- Device
- Lead sponsor
- Marker Therapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 7
- States / cities
- Little Rock, Arkansas • Albuquerque, New Mexico • Portland, Oregon + 4 more
- Conditions
- Immune-related Adverse Event
- Interventions
- Spectra Optia Apheresis System
- Device
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Granulocyte/ Polymorphonuclear Cells
- Interventions
- Granulocyte/Polymorphonuclear Cell Collection (COBE Spectra System), Granulocyte/Polymorphonuclear Cell Collection (Spectra Optia System)
- Device
- Lead sponsor
- Terumo BCT
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Cincinnati, Ohio • Milwaukee, Wisconsin
- Conditions
- Leukapheresis
- Interventions
- Mononuclear cell collection.
- Device
- Lead sponsor
- Terumo BCT
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 3
- States / cities
- Emeryville, California • Memphis, Tennessee • Milwaukee, Wisconsin